iNova Pharmaceuticals, in partnership with CoVentured, is thrilled to launch iPitch 2024, a global crowdsourcing initiative aimed at discovering the latest, science-backed innovations in the field of ‘wound care’.

iPitch offers product and packaging developers, innovators, research and development labs, licensors, and certified manufacturers the opportunity to connect with iNova and showcase innovative consumer health products that have the potential for commercialisation.

It provides a wonderful opportunity for anyone with new, unique, or next-generation solutions, but who may not have the resources or expertise to bring their innovations to market or are looking for an experienced, global commercialisation partner with a strong track record of success.

Filomena Maiese, iNova Executive Director – Portfolio Strategy & Innovation, said:
“This is an exciting time of growth for iNova as we launch into new consumer health categories and expand our geographic reach following the acquisition of the iconic BETADINE® portfolio from Mundipharma International earlier this year.”

After creating a lot of buzz in 2020 and by leveraging the power of global connectivity, the previous iPitch initiative executed by iNova received hundreds of diverse product and formulation ideas from around the world. As a result, iNova launched new products that otherwise would not have had a chance to make it to consumers.

“This year, we are leveraging the iPitch platform to seek breakthrough innovation and new products in the field of ‘wound care,’ which we know is ready for disruption in the consumer health space. Research tells us that overwhelmingly consumers are seeking ‘self-care’ options for the management of their everyday health and wellbeing,” said Filomena.

“This particular iPitch challenge aims to discover innovative solutions across the wound care cycle from ‘clean and treat’ to ‘wound healing and recovery,’ through to ‘scar minimisation.’”

“With our global network of innovation and distribution partners, and expertise in acquiring, building, and launching trusted consumer healthcare brands, iNova is a great partner of choice for product developers, owners, and licensors,” continued Filomena.

With a trusted reputation among consumers and healthcare professionals, iNova is recognised as an innovative go-to partner of choice in the consumer health industry. The company is uniquely positioned to offer access to well-established operating platforms and broad distribution networks across Asia, the Middle East, Africa, Europe, Australia, and New Zealand.

iPitch is open for applications for six weeks, ending 15 November 2024. Further information about iPitch, including how to submit applications, can be found at https://info.ecosystm.io/ipitch.

Image from freepik.com.

iNova Pharmaceuticals, in partnership with CoVentured, is thrilled to launch iPitch 2024, a global crowdsourcing initiative aimed at discovering the latest, science-backed innovations in the field of ‘wound care’.

iPitch offers product and packaging developers, innovators, research and development labs, licensors, and certified manufacturers the opportunity to connect with iNova and showcase innovative consumer health products that have the potential for commercialisation.

It provides a wonderful opportunity for anyone with new, unique, or next-generation solutions, but who may not have the resources or expertise to bring their innovations to market or are looking for an experienced, global commercialisation partner with a strong track record of success.

Filomena Maiese, iNova Executive Director – Portfolio Strategy & Innovation, said:
“This is an exciting time of growth for iNova as we launch into new consumer health categories and expand our geographic reach following the acquisition of the iconic BETADINE® portfolio from Mundipharma International earlier this year.”

After creating a lot of buzz in 2020 and by leveraging the power of global connectivity, the previous iPitch initiative executed by iNova received hundreds of diverse product and formulation ideas from around the world. As a result, iNova launched new products that otherwise would not have had a chance to make it to consumers.

“This year, we are leveraging the iPitch platform to seek breakthrough innovation and new products in the field of ‘wound care,’ which we know is ready for disruption in the consumer health space. Research tells us that overwhelmingly consumers are seeking ‘self-care’ options for the management of their everyday health and wellbeing,” said Filomena.

“This particular iPitch challenge aims to discover innovative solutions across the wound care cycle from ‘clean and treat’ to ‘wound healing and recovery,’ through to ‘scar minimisation.’”

“With our global network of innovation and distribution partners, and expertise in acquiring, building, and launching trusted consumer healthcare brands, iNova is a great partner of choice for product developers, owners, and licensors,” continued Filomena.

With a trusted reputation among consumers and healthcare professionals, iNova is recognised as an innovative go-to partner of choice in the consumer health industry. The company is uniquely positioned to offer access to well-established operating platforms and broad distribution networks across Asia, the Middle East, Africa, Europe, Australia, and New Zealand.

iPitch is open for applications for six weeks, ending 15 November 2024. Further information about iPitch, including how to submit applications, can be found at https://info.ecosystm.io/ipitch.

Image from freepik.com.

iNova Pharmaceuticals, in partnership with CoVentured, is thrilled to launch iPitch 2024, a global crowdsourcing initiative aimed at discovering the latest, science-backed innovations in the field of ‘wound care’.

iPitch offers product and packaging developers, innovators, research and development labs, licensors, and certified manufacturers the opportunity to connect with iNova and showcase innovative consumer health products that have the potential for commercialisation.

It provides a wonderful opportunity for anyone with new, unique, or next-generation solutions, but who may not have the resources or expertise to bring their innovations to market or are looking for an experienced, global commercialisation partner with a strong track record of success.

Filomena Maiese, iNova Executive Director – Portfolio Strategy & Innovation, said:
“This is an exciting time of growth for iNova as we launch into new consumer health categories and expand our geographic reach following the acquisition of the iconic BETADINE® portfolio from Mundipharma International earlier this year.”

After creating a lot of buzz in 2020 and by leveraging the power of global connectivity, the previous iPitch initiative executed by iNova received hundreds of diverse product and formulation ideas from around the world. As a result, iNova launched new products that otherwise would not have had a chance to make it to consumers.

“This year, we are leveraging the iPitch platform to seek breakthrough innovation and new products in the field of ‘wound care,’ which we know is ready for disruption in the consumer health space. Research tells us that overwhelmingly consumers are seeking ‘self-care’ options for the management of their everyday health and wellbeing,” said Filomena.

“This particular iPitch challenge aims to discover innovative solutions across the wound care cycle from ‘clean and treat’ to ‘wound healing and recovery,’ through to ‘scar minimisation.’”

“With our global network of innovation and distribution partners, and expertise in acquiring, building, and launching trusted consumer healthcare brands, iNova is a great partner of choice for product developers, owners, and licensors,” continued Filomena.

With a trusted reputation among consumers and healthcare professionals, iNova is recognised as an innovative go-to partner of choice in the consumer health industry. The company is uniquely positioned to offer access to well-established operating platforms and broad distribution networks across Asia, the Middle East, Africa, Europe, Australia, and New Zealand.

iPitch is open for applications for six weeks, ending 15 November 2024. Further information about iPitch, including how to submit applications, can be found at https://info.ecosystm.io/ipitch.

Image from freepik.com.

iNova Pharmaceuticals, in partnership with CoVentured, is thrilled to launch iPitch 2024, a global crowdsourcing initiative aimed at discovering the latest, science-backed innovations in the field of ‘wound care’.

iPitch offers product and packaging developers, innovators, research and development labs, licensors, and certified manufacturers the opportunity to connect with iNova and showcase innovative consumer health products that have the potential for commercialisation.

It provides a wonderful opportunity for anyone with new, unique, or next-generation solutions, but who may not have the resources or expertise to bring their innovations to market or are looking for an experienced, global commercialisation partner with a strong track record of success.

Filomena Maiese, iNova Executive Director – Portfolio Strategy & Innovation, said:
“This is an exciting time of growth for iNova as we launch into new consumer health categories and expand our geographic reach following the acquisition of the iconic BETADINE® portfolio from Mundipharma International earlier this year.”

After creating a lot of buzz in 2020 and by leveraging the power of global connectivity, the previous iPitch initiative executed by iNova received hundreds of diverse product and formulation ideas from around the world. As a result, iNova launched new products that otherwise would not have had a chance to make it to consumers.

“This year, we are leveraging the iPitch platform to seek breakthrough innovation and new products in the field of ‘wound care,’ which we know is ready for disruption in the consumer health space. Research tells us that overwhelmingly consumers are seeking ‘self-care’ options for the management of their everyday health and wellbeing,” said Filomena.

“This particular iPitch challenge aims to discover innovative solutions across the wound care cycle from ‘clean and treat’ to ‘wound healing and recovery,’ through to ‘scar minimisation.’”

“With our global network of innovation and distribution partners, and expertise in acquiring, building, and launching trusted consumer healthcare brands, iNova is a great partner of choice for product developers, owners, and licensors,” continued Filomena.

With a trusted reputation among consumers and healthcare professionals, iNova is recognised as an innovative go-to partner of choice in the consumer health industry. The company is uniquely positioned to offer access to well-established operating platforms and broad distribution networks across Asia, the Middle East, Africa, Europe, Australia, and New Zealand.

iPitch is open for applications for six weeks, ending 15 November 2024. Further information about iPitch, including how to submit applications, can be found at https://info.ecosystm.io/ipitch.

Image from freepik.com.

iNova Pharmaceuticals, in partnership with CoVentured, is thrilled to launch iPitch 2024, a global crowdsourcing initiative aimed at discovering the latest, science-backed innovations in the field of ‘wound care’.

iPitch offers product and packaging developers, innovators, research and development labs, licensors, and certified manufacturers the opportunity to connect with iNova and showcase innovative consumer health products that have the potential for commercialisation.

It provides a wonderful opportunity for anyone with new, unique, or next-generation solutions, but who may not have the resources or expertise to bring their innovations to market or are looking for an experienced, global commercialisation partner with a strong track record of success.

Filomena Maiese, iNova Executive Director – Portfolio Strategy & Innovation, said:
“This is an exciting time of growth for iNova as we launch into new consumer health categories and expand our geographic reach following the acquisition of the iconic BETADINE® portfolio from Mundipharma International earlier this year.”

After creating a lot of buzz in 2020 and by leveraging the power of global connectivity, the previous iPitch initiative executed by iNova received hundreds of diverse product and formulation ideas from around the world. As a result, iNova launched new products that otherwise would not have had a chance to make it to consumers.

“This year, we are leveraging the iPitch platform to seek breakthrough innovation and new products in the field of ‘wound care,’ which we know is ready for disruption in the consumer health space. Research tells us that overwhelmingly consumers are seeking ‘self-care’ options for the management of their everyday health and wellbeing,” said Filomena.

“This particular iPitch challenge aims to discover innovative solutions across the wound care cycle from ‘clean and treat’ to ‘wound healing and recovery,’ through to ‘scar minimisation.’”

“With our global network of innovation and distribution partners, and expertise in acquiring, building, and launching trusted consumer healthcare brands, iNova is a great partner of choice for product developers, owners, and licensors,” continued Filomena.

With a trusted reputation among consumers and healthcare professionals, iNova is recognised as an innovative go-to partner of choice in the consumer health industry. The company is uniquely positioned to offer access to well-established operating platforms and broad distribution networks across Asia, the Middle East, Africa, Europe, Australia, and New Zealand.

iPitch is open for applications for six weeks, ending 15 November 2024. Further information about iPitch, including how to submit applications, can be found at https://info.ecosystm.io/ipitch.

Image from freepik.com.

iNova Pharmaceuticals, in partnership with CoVentured, is thrilled to launch iPitch 2024, a global crowdsourcing initiative aimed at discovering the latest, science-backed innovations in the field of ‘wound care’.

iPitch offers product and packaging developers, innovators, research and development labs, licensors, and certified manufacturers the opportunity to connect with iNova and showcase innovative consumer health products that have the potential for commercialisation.

It provides a wonderful opportunity for anyone with new, unique, or next-generation solutions, but who may not have the resources or expertise to bring their innovations to market or are looking for an experienced, global commercialisation partner with a strong track record of success.

Filomena Maiese, iNova Executive Director – Portfolio Strategy & Innovation, said:
“This is an exciting time of growth for iNova as we launch into new consumer health categories and expand our geographic reach following the acquisition of the iconic BETADINE® portfolio from Mundipharma International earlier this year.”

After creating a lot of buzz in 2020 and by leveraging the power of global connectivity, the previous iPitch initiative executed by iNova received hundreds of diverse product and formulation ideas from around the world. As a result, iNova launched new products that otherwise would not have had a chance to make it to consumers.

“This year, we are leveraging the iPitch platform to seek breakthrough innovation and new products in the field of ‘wound care,’ which we know is ready for disruption in the consumer health space. Research tells us that overwhelmingly consumers are seeking ‘self-care’ options for the management of their everyday health and wellbeing,” said Filomena.

“This particular iPitch challenge aims to discover innovative solutions across the wound care cycle from ‘clean and treat’ to ‘wound healing and recovery,’ through to ‘scar minimisation.’”

“With our global network of innovation and distribution partners, and expertise in acquiring, building, and launching trusted consumer healthcare brands, iNova is a great partner of choice for product developers, owners, and licensors,” continued Filomena.

With a trusted reputation among consumers and healthcare professionals, iNova is recognised as an innovative go-to partner of choice in the consumer health industry. The company is uniquely positioned to offer access to well-established operating platforms and broad distribution networks across Asia, the Middle East, Africa, Europe, Australia, and New Zealand.

iPitch is open for applications for six weeks, ending 15 November 2024. Further information about iPitch, including how to submit applications, can be found at https://info.ecosystm.io/ipitch.

Image from freepik.com.